Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002829 · ClinicalTrials.gov registry record · Phase 2
Bone Marrow Transplantation in Treating Patients With Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00002829: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00002829 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002829, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation in treating patients with recurrent or residual low-grade lymphoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Mesna
- DRUG Etoposide
- PROCEDURE Bone Marrow Transplantation
- BIOLOGICAL Recombinant Interferon Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1994-02 |
| Est. Completion | 2002-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002829
The ClinicalTrials.gov registry entry for NCT00002829 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00002829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002829 about?
NCT00002829 is a clinical study titled "Bone Marrow Transplantation in Treating Patients With Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for lymphoma. Bone marrow transplantation may be able to replace immune cells t...
What is the current status of trial NCT00002829?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1994-02. Estimated completion is 2002-04.
What interventions are being tested in trial NCT00002829?
The interventions under investigation include: Cyclophosphamide (DRUG), Mesna (DRUG), Etoposide (DRUG), Bone Marrow Transplantation (PROCEDURE), Recombinant Interferon Alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002829?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.